---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-048529"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2022-02-22T23:59:59+00:00"
generated_at: "2026-06-27T05:50:15.497601+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cerus Q4 revenue $50.1M (+49% YoY); reiterates FY2022 product revenue guidance $157-164M

## Summary
- Q4 product revenue $39.9M (+41% YoY); net loss narrowed to $9.1M ($0.05/sh) from $14.4M.
- FY2021 total revenue $159.5M (+40% YoY); product revenue $130.9M (+42% YoY).
- FY2022 product revenue guidance reaffirmed at $157-164M, representing 20-25% growth.
- Two blood centers obtained BLA approvals for INTERCEPT Fibrinogen Complex (IFC), enabling interstate sales.
- Cash, equivalents and short-term investments $129.4M at Dec 31, 2021; net cash used in ops $33.9M.

## SEC filing metadata
- accession: 0001193125-22-048529
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2022-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000119312522048529/0001193125-22-048529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000119312522048529/d317573d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-048529
- JSON: https://secwatch.observer/filing/0001193125-22-048529.json
- Plain text: https://secwatch.observer/filing/0001193125-22-048529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.